egfr-tkis治疗egfr突变阳性的晚期非小细胞肺腺癌的临床研究

《egfr-tkis治疗egfr突变阳性的晚期非小细胞肺腺癌的临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089___学号或申请号20132424_中国图书分类号R734___HebeiMedicalUniversity硕士学位论文科学学位EGFR-TKIs治疗EGFR突变阳性的晚期非小细胞肺腺癌的临床研究研究生：孙红娜导师：丁翠敏教授专业：内科学二级学院：河北医科大学第四医院2013年10月～2016年2月万方数据河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师（或指导小组）的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单

2、位河北医科大学，试验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：导师签章：二级学院领导盖章：年月日河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果，指导教师对此进行了审定。本论文由本人独立撰写，文责自负。研究生签名：导师签章：年月日万方数据目录中文摘要·············································································1英文摘要·····

3、········································································4英文缩写·············································································8研究论文EGFR-TKIs治疗EGFR突变阳性的晚期非小细胞肺腺癌的临床研究前言·············································································9材料与方法··················

4、··················································11结果·············································································14附图·············································································16附表·············································································21讨

5、论·············································································26结论·············································································31参考文献·······································································32综述晚期非小细胞肺癌靶向治疗进展······································35致谢

6、···················································································52个人简历·············································································53万方数据中文摘要EGFR-TKIs治疗EGFR突变阳性的晚期非小细胞肺腺癌的临床研究摘要目的：肺癌（LungCancer）是目前全球最高发的恶性肿瘤之一。在我国，肺癌的发病率和死亡率也与全球发展趋势相似，呈逐年上升趋势。其中非小细胞肺癌（NonSmallC

7、ellLungCancer,NSCLC）占肺癌比例最大，约占80%以上。对于早期的非小细胞肺癌患者，可以行手术治疗，术后的5年生存率最高可达50%。但大部分肺癌患者发现即为晚期，失去了手术机会，无法行手术切除。因此对于晚期非小细胞肺癌，化疗、放疗、分子靶向治疗成为主要方式，其中以铂类为基础联合第三代化疗药物的治疗方案仍是目前的一线标准方案，虽能延长患者的生存，但副反应大，效果仍欠佳。而EGFR-TKIs的问世，让临床医生眼前为之一亮，使现有的临